Drug intelligence / Profile preview

AUP-60

Development stage: Unknown
Lead developer: Aurealis Therapeutics
Modality: Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics

Overview

AUP-60 is a recombinant LBP (likely referring to a recombinant lipopolysaccharide-binding protein or similar biologic) under development by Aurealis Therapeutics AG. It is in the discovery phase and is being investigated for immune system diseases and skin and musculoskeletal diseases, with active indications including onycholysis and rheumatic diseases. The drug represents an early-stage, multi-targeting therapeutic approach, consistent with Aurealis Therapeutics' platform of genetically engineered live biotherapeutic products designed to deliver therapeutic proteins directly at disease sites[2][6][10].

Beyond the preview

Go deeper on AUP-60.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUP-60.

Explore the full profile